SCHEMBL7226902

SCHEMBL7226902

CN(Cc1ccc([N+](=O)[O-])cc1)Cc1ccc(C(F)(F)F)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PYCR1 P32322 2/20 0.57
MMP1 P03956 2/20 0.53
CRHBP P24387 1/20 0.51
CRHR2 Q13324 1/20 0.51
KCNH2 Q12809 1/20 0.51
TGM2 P21980 1/20 0.47
TMEM97 Q5BJF2 2/20 0.46
SIGMAR1 Q99720 2/20 0.46
NR1D1 P20393 1/20 0.45
CA1 P00915 1/20 0.44
CA2 P00918 1/20 0.44
CA5A P35218 1/20 0.44
CA9 Q16790 1/20 0.44
ALDH1A1 P00352 1/20 0.43
LOXL2 Q9Y4K0 1/20 0.43
MEN1 O00255 1/20 0.43
LMNA P02545 1/20 0.43
MAPT P10636 1/20 0.43
KMT2A Q03164 1/20 0.43
MMP2 P08253 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3153145 0.82 PYCR1 (0.62) PYCR1MMP1CRHBPCRHR2KCNH2
SCHEMBL439543 0.81 CA1 (0.60) TGM2CA1CA2CA5ACA9
SCHEMBL2351816 0.81 POLB (0.67) PYCR1CRHBPCRHR2KCNH2TMEM97
SCHEMBL3143221 0.80 CRHBP (0.71) PYCR1CRHBPCRHR2KCNH2TMEM97
SCHEMBL3148248 0.80 ACHE (0.64) PYCR1MMP1CRHBPCRHR2KCNH2
SCHEMBL3152135 0.79 PYCR1 (0.62) PYCR1MMP1CRHBPCRHR2KCNH2
SCHEMBL3148676 0.79 PYCR1 (0.62) PYCR1CRHBPCRHR2KCNH2TMEM97
SCHEMBL3154646 0.78 PYCR1 (0.66) PYCR1CRHBPCRHR2KCNH2TMEM97
SCHEMBL20776926 0.77 HSD11B1 (0.46) MMP1CRHBPCRHR2TGM2NR1D1
SCHEMBL19049131 0.77 TMEM97 (0.61) PYCR1TMEM97SIGMAR1CA2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6545035-B1 Having effect on various kinases and cycline/CDK complexes and on the proliferation of various tumour cells. BOEHRINGER INGELHEIM PHARMA KG (DE) 2003-04-08 US disclosed
US-6319918-B1 FOR LYMPHOMA OR SOLID TUMORS TREATMENT BOEHRINGER INGELHEIM PHARMA KG (DE) 2001-11-20 US disclosed
EP-1100779-A1 SUBSTITUTED INDOLINONES, THE PRODUCTION THEREOF AND THEIR USE AS MEDICAMENTS Boehringer Ingelheim Pharma KG (DE) 2001-05-23 EP disclosed
WO-2000073297-A1 SUBSTITUTED INDOLINONE AS TYROSINE KINASE INHIBITORS BOEHRINGER INGELHEIM PHARMA KG (DE) 2000-12-07 WO disclosed
WO-1999062882-A1 SUBSTITUTED INDOLINONES, THE PRODUCTION THEREOF AND THEIR USE AS MEDICAMENTS BOEHRINGER INGELHEIM PHARMA KG (DE) 1999-12-09 WO disclosed